Zymeworks Inc. (NASDAQ:ZYME) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET
Company Participants
Kenneth H. Galbraith – Chairman of the Board, CEO & President
Leone D. Patterson – Executive VP and Chief Business & Financial Officer
Paul A. Moore – Chief Scientific Officer
Sabeen Mekan – Senior Vice President of Clinical Development
Shrinal Inamdar – Director of Investor Relations
Conference Call Participants
Charles Yue-Wen Zhu – LifeSci Capital, LLC, Research Division
Lut Ming Cheng – JPMorgan Chase & Co, Research Division
Phoebe Tan – Jefferies LLC, Research Division
Stephen Douglas Willey – Stifel, Nicolaus & Company, Incorporated, Research Division
Yaron Benjamin Werber – TD Cowen, Research Division
Yigal Dov Nochomovitz – Citigroup Inc., Research Division
Operator
Thank you for standing by. This is the conference operator. Welcome to Zymeworks Second Quarter 2025 Results Conference Call and Webcast. [Operator Instructions] The conference is being recorded. [Operator Instructions]
I would now like to turn the conference over to Shrinal Inamdar, Senior Director of Investor Relations. Please go ahead.
Shrinal Inamdar
Thank you, operator, and good afternoon, everyone. Thanks for joining our second quarter 2025 results conference call. Before we begin, I’d like to remind you that we will be making a number of forward-looking statements during this call, including, without limitation, those forward-looking statements identified in our slides and the accompanying oral commentary. Forward-looking statements are based upon our current expectations and various assumptions and are subject to the usual risks and uncertainties associated with companies in our industry and our stated development. For discussion of these risks and uncertainties, we refer you to the latest SEC filings as found on our website and as filed with the SEC.
In a moment, I will hand over to Leone Patterson, our Executive Vice President and Chief Business and Financial Officer, who will provide
Credit: Source link
